Illumina (NASDAQ: ILMN)
Illumina Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Illumina Company Info
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
News & Analysis
Why Illumina Stock Zoomed Higher on Thursday
The company's chances for winning an important legal battle have improved dramatically.
Why Illumina Stock Mashed the Market on Monday
Investors usually get more bullish when a top manager buys more heavily into their company.
Investing in Artificial Intelligence (AI) ETFs
There are several options for investors looking to diversify into AI.
Why Illumina Rallied 36.6% in December
The beaten-down gene sequencing company is getting a further shakeup.
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
Is the Worst Over for Illumina Stock?
There's reason to believe that the future is starting to look better.
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Its core revenue won't grow, and that's not even its biggest problem at the moment.
Down 15% in 2023, Should You Buy the Dip With Illumina Stock?
Illumina's future is looking a bit dim at the moment.
Valuation
Podcast Episodes
Illumina CEO Steps Down; Grail Soap Opera Continues
And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles."
Why Illumina Could Be a Health Tech Powerhouse for Your Portfolio
The sky is the limit for the leader in DNA sequencing.
Our Top Stock Ideas in Silicon Valley’s Biggest Bet in Healthcare
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
Better Buy: Illumina or Gilead Sciences?
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
Earnings Transcripts
Illumina, inc (ILMN) Q3 2021 Earnings Call Transcript
ILMN earnings call for the period ending September 30, 2021.
Illumina, inc (ILMN) Q2 2021 Earnings Call Transcript
ILMN earnings call for the period ending June 30, 2021.
Illumina Inc (ILMN) Q1 2021 Earnings Call Transcript
ILMN earnings call for the period ending March 31, 2021.
Illumina Inc (ILMN) Q4 2020 Earnings Call Transcript
ILMN earnings call for the period ending January 3, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.